Acute myeloid leukemia (AML) is a myeloid cell cancer characterized by rapid growth and accumulation of abnormal white blood cells in bone marrow and blood. These malignant cells interfere with the normal production of red blood cells and platelets, causing anemia and pathologic bleeding. AML is caused by genetic changes that result in increased cellular growth and proliferation, and impaired maturation.

Approximately 13,000 new AML cases occur in the U.S. each year. AML may occur at any age; however, the disease is more common in older patients, with an average age at diagnosis of approximately 60 years.

Cytogenetic and molecular testing for AML are both important for assessing your patient’s prognosis. Versiti’s experienced team stands ready to be your partner in test utilization decisions, test result interpretation and treatment selection.

Versiti’s AML testing algorithm uses a cascade of molecular tests that detect a variety of favorable and unfavorable biomarkers associated with AML.

Additionally, germline mutations in CEBPA have been found in familial AML. Versiti offers AML Familial Evaluation testing for inherited CEBPA mutations.